Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Advanced Solid TumorsLymphomas
Interventions
DRUG

Plitidepsin and Sorafenib

Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).

DRUG

Gemcitabine and Plitidepsin

Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).

Trial Locations (2)

94800

Institut Gustave Roussy, Villejuif

08901

The Cancer Institute of New Jersey (CINJ), New Brunswick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

PharmaMar

INDUSTRY